Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel

Dasatinib is a potent oral tyrosine kinase inhibitor which targets several kinases, including the SRC family kinases. SRC family kinases have been implicated in androgen therapy resistance that often develops in metastatic castration-resistant prostate cancer (mCRPC), which drives the need for non-a...

Descripción completa

Detalles Bibliográficos
Autores principales: Araujo, John C, Trudel, Geralyn C, Paliwal, Prashni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601649/
https://www.ncbi.nlm.nih.gov/pubmed/23516140
http://dx.doi.org/10.2147/CMAR.S41667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601649/
https://www.ncbi.nlm.nih.gov/pubmed/23516140
http://dx.doi.org/10.2147/CMAR.S41667

Ejemplares similares